Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The Queen of Hearts AI-ECG model just became the first to receive FDA De Novo authorization for detecting STEMI and STEMI equivalents in patients with suspected acute coronary syndromes. Backed by 20+ peer-reviewed studies and over 40,000 patients, the tool dramatically cuts false-positive cath lab activations and speeds up treatment. Multiple US health systems were already waiting for this green light to go live.
The Queen of Hearts AI-ECG model, developed by Powerful Medical, has received FDA De Novo authorization — the first of its kind specifically for AI-driven detection of STEMI and STEMI equivalents in patients with suspected acute coronary syndromes. The authorization also covers triage, prioritization, and clinician notification, going beyond simple detection. Multiple US health systems already have the platform integrated and were essentially waiting for this regulatory green light to go live.
The tool, deployed through the PMcardio platform, is backed by more than 20 peer-reviewed studies involving over 40,000 patients. It's expected to be especially impactful at non-PCI centers, where cardiology expertise may be limited — and it includes an explainability feature that shows why an ECG is flagged as STEMI-positive, helping educate frontline physicians in real time.
Why it matters: Faster, more accurate STEMI detection means shorter times to treatment and fewer unnecessary cath lab activations — a meaningful advance for both patients and health systems. Experts predict this will quickly become the standard of care for STEMI management across the US.
